Letters to the Editor

MK2 is a therapeutic target for high-risk multiple myeloma

Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA;
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China;
China Pharmaceutical University, Nanjing, China;
Laboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing, China;
Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine;
Department of Pathology, The First Affiliated Hospital of Nanjing University of Chinese Medicine;
Department of Pathology, School of Medicine, University of Iowa, Iowa City, USA;
School of Medicine and Life Sciences, Nanjing University of Chinese Medicine;
Nanjing University of Chinese Medicine, Nanjing, China
Vol. 106 No. 6 (2021): June, 2021 https://doi.org/10.3324/haematol.2017.182121